Atara Biotherapeutics (ATRA) EBT (2013 - 2026)
Atara Biotherapeutics' (ATRA) quarterly EBT came in at -$4.1 million in Q1 2026, down 110.91% YoY from $38.0 million in Q1 2025, and down 22.34% on a QoQ basis from -$3.4 million in Q4 2025.
Atara Biotherapeutics (ATRA) EBT (2013 - 2026) Analysis & Trends
Atara Biotherapeutics (ATRA) has 14 years of EBT data on file, last reported at -$4.1 million in Q1 2026.
- Quarterly EBT fell 110.91% year-over-year to -$4.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$9.4 million (up 39.92% YoY) and the FY2025 annual result came in at $32.7 million, up 138.33% from the prior year.
- EBT declined to -$4.1 million in Q1 2026, from -$3.4 million in the prior quarter.
- In the past five years, EBT ranged from a high of $38.0 million in Q1 2025 to a low of -$88.1 million in Q1 2022.
- A 5-year average of -$33.0 million and a median of -$21.9 million in 2024 frame the typical range for EBT.
- Annual changes were most pronounced in 2023 — EBT plunged 485.07% — and 2025, when it soared 219.8%.
- Tracing ATRA's EBT over 5 years: stood at -$74.6 million in 2022, then advanced by 18.95% to -$60.4 million in 2023, then jumped by 78.97% to -$12.7 million in 2024, then surged by 73.35% to -$3.4 million in 2025, then dropped by 22.34% to -$4.1 million in 2026.
- The last three EBT figures came in at -$4.1 million (Q1 2026), -$3.4 million (Q4 2025), and -$4.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 177.81 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -11.37 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -264.70 Mn |
| 10 | Atara Biotherapeutics | 140.71 Mn | 124.16 Mn | 439,000.00 | -4.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.83 Mn |
| Mar 31, 2026 | -4.15 Mn |
| Dec 31, 2025 | -3.39 Mn |
| Sep 30, 2025 | -4.28 Mn |
| Jun 30, 2025 | 2.39 Mn |
| Mar 31, 2025 | 38.01 Mn |
| Dec 31, 2024 | -12.71 Mn |
| Sep 30, 2024 | -21.93 Mn |
| Jun 30, 2024 | -19.05 Mn |
| Mar 31, 2024 | -31.73 Mn |
| Dec 31, 2023 | -60.44 Mn |
| Sep 30, 2023 | -69.82 Mn |
| Jun 30, 2023 | -71.11 Mn |
| Mar 31, 2023 | -74.75 Mn |
| Dec 31, 2022 | -74.57 Mn |
| Sep 30, 2022 | -84.08 Mn |
| Jun 30, 2022 | 18.47 Mn |
| Mar 31, 2022 | -88.11 Mn |
| Dec 31, 2021 | -93.53 Mn |
| Sep 30, 2021 | -84.66 Mn |